(A) Stereo view of the VLY ml -CD59 D22A complex asymmetric unit showing the intertwined nature of the CDC "dimer". One VLY ml monomer is colored by domain as in Figure 1 , with its associated CD59 D22A molecule in grey. The second VLY ml monomer is colored pink with its CD59 D22A in orange. (B) Orthogonal views of the solvent accessible surface of VLY ml colored by local electrostatics (red: -1kT/e to blue: +1Kt/e) showing the disparity in the charge on the two faces of the protein. Electrostatics were calculated using the APBS plugin (Baker et al., 2001) for PyMOL (Schrodinger, 2015) . The upper data set is from a static sample at 5.6 mg/ml. The lower data set is for a SEC-SAXS sample at 0.12 mg/ml. For each data set, the theoretical scattering profile of the crystallographic model of the ILY ml -CD59 D22A complex was fitted to the experimental data using CRYSOL (Svergun et al., 1995) and is shown as a solid black line (χ CRYSOL = 0.845 and 0.309 for the static and SEC data sets, respectively). The fit of the theoretical scattering profile of a representative dummy atom model generated by DAMMIF (Franke and Svergun, 2009 ) is shown as a solid red line (χ DAMMIF = 0.749 and 0.304 for the static and SEC data sets, respectively). (B) Guinier plots. Data points satisfied q.R g <1.3 for both data sets are shown (R g = 37.9 ± 0.2 Å and 37.4 ± 2.2 Å for the static and SEC data sets, respectively. (C) The P(r) pair distance vector distribution function generated from the static SAXS data set using DATGNOM (Petoukhov et al., 2012) . wt a stabilising aromatic box forms between the F47 side-chain of CD59 (grey) and the side-chains of Y423 (face-packed) and Y421 (edge-face packed) from VLY wt . W481, the last tryptophan residue of the conserved undecapeptide motif is packed against Y421 in another edge-face interaction, further locking the aromatic box in to place. (B) In ILY wt R480 sits between the aromatic rings of F47 from CD59 and Y436 of ILY wt and forms a salt bridge (red dashed lines) with E58 of CD59. The second tyrosine of the ILY wt Y-X-Y motif, Y434 (not shown), does not appear to be involved in the interaction. 
SUPPLEMENTAL TABLES

SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Related to main-text Experimental Procedures
Cloning, Expression and Purification
The E. coli codon optimized VLY gene construct, lacking the 31 residue N terminal signal sequence, pET28a/coVLY31, has been previously described (Gelber et al., 2008) . VLY coding sequence A31 -D516 (VLY 31 ) was amplified by PCR and cloned into pMCSg7 by LIC cloning. The monomer locked form, VLY 31 ml containing mutations T333C and I348C was created using the QuikChange™ Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. The monomer locked mutant of ILY (ILY ml , T346 and I361 mutated to cysteines) has been previously described (LaChapelle et al., 2009 
CD59
CD59 was amplified from an IMAGE:4776621 cDNA clone of huCD59 using oligos: 5' TACTTCCAATCCAATGCTCTGCAGTGCTACAACTGTCCT;3'TTATCCACTTCCAATTAATTTTCAAGC TGTTCGTTAAA and was cloned into vector pMCSG7. This encoded a His 6 -TEV-CD59 fusion protein which after TEV cleavage of the hexahistidine tag yielded the CD59 coding region of the mature protein [L1-P103 with an N terminal additional serine, asparagine, alanine]. Point mutation D22A was introduced with oligos: 5' TGTTCATCTGCCTTTGATGCG3' and complement 5' CGCATCAAAGGCAGATGAACA 3' using the Quik Change Mutagenesis kit (Stratagene), according to manufacturer's instructions. His 6 -TEV-CD59 D22A was expressed in E. coli BL21 (DE3) pREP4 in Luria Broth (LB) medium at 37°C. The cell pellet was resuspended at 21°C in lysis buffer (50 mM Tris pH 8.0, 100 mM NaCl, 10 % (v/v) glycerol, 0.1% Triton X-100, 100 µM PMSF, 10 µg/ml lysozyme, 10 µg/ml DNAse 1. Cells were lysed by incubating at 21°C shaking for 1 hour, then sonicated 6 x 10 seconds. CD59 containing inclusion bodies were isolated by centrifugation at 20,000g for 20 minutes. Inclusion bodies were solubilized in Buffer A, pH 8.0 with 8 M urea (500 mM NaCl, 25 mM Tris, 20 mM imidazole, 8 M urea, pH 8.0). His 6 -TEV-CD59 D22A was purified on a 5 ml HisTrap TM HP column (GE), equilibrated in Buffer A, pH 8.0 with 8 M urea. The column was washed with 50 ml Buffer A, pH 8.0 with 8 M urea. His 6 -TEV-CD59 D22A was eluted from the column with Buffer B (25 mM Tris, 500 mM NaCl, 400 mM imidazole, pH 8.0) with 8 M urea. Fractions containing His 6 -TEV-CD59
D22A were pooled and refolded as described by Leath et al. (2007) . After refolding, His 6 -TEV-CD59 D22A was concentrated and dialyzed into 20 mM Tris pH 7.2 and 150 mM NaCl and incubated with a 1:50 molar ratio of His 6 -TEV-CD59
D22A to TEV to remove the hexahistidine tag. The protein solution was dialyzed into 20 mM Tris, 500 mM NaCl, 20 mM imidazole, pH 8.0 and purified on a 5 ml HisTrap TM HP column (GE), equilibrated in Buffer A, pH 8.0, to remove the His tag and His-TEV. The purified CD59 D22A passed through the column and was dialyzed into 20 mM HEPES, pH 7.0, 150 mM NaCl, at 4°C for 16 hours. Dialyzed CD59 D22A was further purified by SEC on a Superdex 75 26/60 column in 20 mM HEPES, pH 7.2, 150 mM NaCl. Fractions containing monomeric CD59 D22A protein (as monitored by SDS PAGE) were pooled and concentrated to 10 mg/ml and stored at -80°C.
CDC-CD59 Complex Formation
Either VLY ml or His 6 -ILY ml were mixed with monomeric CD59 D22A in a 1:3 molar ratio and dialyzed into 20 mM HEPES, pH 7.0, 150 mM NaCl, at 21°C for 2 hours. The dialyzed complex was purified by SEC on a GE Superdex 200 26/60 column in 20 mM HEPES pH 7.0 and 150 mM NaCl. Fractions containing the VLY ml -CD59 D22A complex or the ILY ml -CD59 D22A complex were pooled and concentrated to 3.5 mg/ml and 6 mg/ml respectively, and stored at -80°C. Complex formation was verified by comparative SEC of monomer locked CDC and CDC-CD59 complex and SDS-PAGE of complex peak fractions.
Crystallizations VLY ml -CD59 D22A Complex Initial crystallization trials of the VLY ml -CD59 D22A complex were set up at 21 ºC on a Crystal Gryphon robot (ARI, Sunnywale CA, USA) in 96 well sitting drop format using Rigaku UV+ 96 plates (AXT, Sydney, Australia). Drops containing 0.2 µl of protein and 0.2 µl of crystallization solution were equilibrated against 35 µl of crystallization solution. Sparse matrix crystallization screens were conducted using MCSG+ screens 1 to 4 (Microlytic, USA) with the VLY ml -CD59 D22A complex at a concentration of 3.9 mg/ml in 20 mM HEPES pH 7.2, 150 mM NaCl. Crystals initially formed in MCSG+ screen 1, condition 25 (0.1 M ammonium acetate, 17% PEG 10 K, 0.1 M Bis-Tris pH 5.5) at 21°C. Optimization of crystallization conditions were performed using the hanging drop vapor diffusion method in Linbro culture plates (ICN, Biochemicals Inc., Ohio, USA) at 21°C. Drops of 1 µl VLY ml -CD59 D22A (2.65 mg/ml) mixed with an equal volume of precipitant were hung over 0.5 ml of well solution consisting of 0.1 M ammonium acetate, 17% PEG 10 K and 0.1 M Bis-Tris pH 5.5. 10 mM MgCl 2 was added to the drop only. Cryoprotection was achieved by the addition of 20% v/v PEG 400 to the drop and incubation at 21°C for 30 minutes before freezing in liquid nitrogen.
ILY ml
Crystallization of ILY ml was performed using the same protocol as previously reported for ILY wt (Polekhina et al., 2004) . Crystals were cryo-protected by transferring to a drop of 100mM MES pH 6.5, 75 mM NaCl, 18% PEG 8000 and directly adding 5% v/v MPD to the drop, every 30 minutes to a final concentration of 20% v/v MPD.
ILY
ml -CD59 D22A Complex Initial crystallization trials were set up at 21 ºC on a Crystal Gryphon robot (ARI, Sunnywale CA, USA) in 96 well sitting drop format using Rigaku UV+ 96 plates (AXT, Sydney, Australia). Drops containing 0.2 µl of protein and 0.2 µl of crystallization solution were equilibrated against 35 µl of crystallization solution. Sparse matrix crystallization screens were conducted using MCSG+ screens 1 to 4 (Microlytic, USA) with the ILY ml CD59 D22A complex at a concentration of 6 mg/ml. Crystals initially formed in MCSG+ screen 3, number 36 (10 % w/v PEG 8000, 0.2 M zinc acetate and 0.1 M MES, pH 6.0). Optimization of crystallization conditions was performed using the hanging drop vapor diffusion method at 21°C. 1 µl of ILY ml -CD59 D22A was mixed with an equal volume of precipitant and hung over 0.5 ml of well solution of 10% w/v PEG 8000, 0.2 M zinc acetate, 100 mM MES pH 6.0 and 1 mM copper sulfate. Prior to freezing the crystals were cryo-protected by adding 4 times 0.2 µl of 10 M LiCl into the drops. The time interval between the additions was approximately 30 minutes.
Data Collection, Structure Determination and Refinement
Data were collected at the MX2 beamline at the Australian Synchrotron (Clayton, Victoria). Data collection was controlled using Blue-Ice software (McPhillips et al., 2002) .
The collected data were processed using the program XDS (Kabsch, 2010). Data from three separate crystals were merged to produce the final dataset. The space group was P2 1 2 1 2 with unit cell dimensions of a = 81.4 Å, b = 141.1 Å, c = 106.8 Å. The asymmetric unit contained two copies of the VLY ml -CD59 D22A complex, with a solvent content of approximately 53% according to Matthews' coefficient calculations (Matthews, 1968) . Molecular replacement was performed using the program PHASER (McCoy et al., 2007) in the PHENIX program suite (Adams et al., 2002 ). The search model was a low resolution (~4 Å) unpublished structure of VLY-CD59 determined from a different crystal form in-house (data not shown). The two CD59 molecules (PDB code: 2J8B, (Leath et al., 2007) ) were located during another round of molecular replacement keeping the VLY structures fixed. Model building was performed with the program COOT (Emsley and Cowtan, 2004 ) and the programs REFMAC 5 (Murshudov et al., 1997) and PHENIX (Adams et al., 2002) were used for refinement. Individual B-factors were refined without the use of NCS constraints and bulk solvent and anisotropic scaling were applied. The final model yielded an R factor and R free of 23.4% and 27.3%, respectively. All residues of both proteins were visible in the electron density map except residues at the N-terminal ends of both VLY ml chains, which were not built as the electron density was not well defined. In addition to the protein components, the final model of the complex includes 137 water molecules. The geometry of the model was good with a Ramachandran plot showing 97.4% of the residues in the allowed regions. Data and refinement statistics are listed in Table 1 .
ILY ml
Data processing was performed using the program XDS (Kabsch, 1993) . The space group was P2 1 2 1 2 with unit cell dimensions of a = 84.5 Å, b = 101.6 Å, c = 175.7 Å. These unit cell dimensions were similar to ILY wt . The program POINTLESS (CCP4 program suite) detected the presence of pseudotranslational symmetry. During molecular replacement calculations this pseudotranslational symmetry was corrected using PHASER (McCoy et al., 2007) which is part of the PHENIX program suite (Adams et al., 2002) . A solution was found with a monomer of ILYwt (PDB code: 1S3R; (Polekhina et al., 2005) ) as a search model. Model building was performed with the program COOT (Emsley and Cowtan, 2004) . Bulk solvent, anisotropic scaling and NCS restraints were applied and individual B-factor and TLS parameters were refined. The model yielded a final R factor and R free of 21.5% and 27.6%, respectively. ILY ml molecule A superimposes onto molecule B with rmsd of 0.5 Å. Due to ambiguous electron density for residues 326 to 341 of monomer A and residues 326 to 340 in monomer B had to be removed. These residues were part of the TMH2 region. Additionally, due to lack of electron density residues 487 to 493 belonging to the trp-rich loop were deleted in monomer A. L1 to L3 loops in domain 4 had patches of bad electron density but the residues were not deleted. The mutation of residues T346 and I361 of ILY ml into cysteines could be confirmed but the expected disulfide bridge between these residues could only be seen in monomer B. Monomer A exhibited poor density in the vicinity of this mutation. Due to the low resolution water molecules could not the placed in the electron density map. Stereochemical analysis of the refined structure using the program PROCHECK (Laskowski et al., 1993 ) gave a value of 99.2% in the allowed regions of the Ramachandran plot. There were 6 outliers (S358 (molecules A and B); I365 (molecules A an B); A319 (molecule B) and L496 (molecule B)) in the structure all located in regions of insufficient electron density. The statistics for data processing and refinement are presented in Table 1 . (Emsley and Cowtan, 2004 ) and the programs REFMAC 5 (Murshudov et al., 1997) and PHENIX (Adams et al., 2002) were used for refinement. Individual B-factor and TLS parameters were refined and bulk solvent and anisotropic scaling was applied. The final model yielded an R factor and R free of 20.2 % and 25.9 %, respectively. All residues of both proteins were visible in the electron density map except residues 327 to 338 of ILY ml , located in TMH2, which were not built as the electron density was not well defined. In addition to the protein components, the final model of the complex includes 127 water molecules and 2 SO 4 2-ions, one bound to Q255 and one to H242, and 7 Zn 2+ ions. The geometry of the model was good with a Ramachandran plot showing 100% of the residues in the allowed regions. Data and refinement statistics are listed in Table 1 .
Small Angle X-ray Scattering SAXS data were collected on the SAXS/WAXS beamline at the Australian Synchrotron (Clayton, Victoria) (Table S1 ) (Kirby et al., 2013) . The X-ray beam size was 250 µm horizontal x 120 µm vertical. Data collection was on a Dectris-Pilatus 200K detector. Sample to detector distance was 2676.22 mm (q-range 0.06 -0.35 Å -1 ) with a 12 Ke V beam and X-ray wavelength of 1.0322 Å. SAXS data from samples of the ILY-CD59 complex were recorded in static mode and using in-line gel filtration (SEC-SAXS) (Gunn et al., 2011) . In static mode, SEC purified, ILY ml -CD59 D22A complex solution (48 µl at 6 mg/ml in 20 mM HEPES pH 7.2, 150 mM NaCl) was automatically sampled from a 96 well plate. Data acquisition was at 298 K with 2 second exposures (2.1 sec. repeat time). In SEC-SAXS mode, samples (48 µl at 6 mg/ml in 20 mM HEPES pH 7.2, 150 mM NaCl) were run with a Wyatt Technology WTC-050N5G SEC column equilibrated in the same buffer. The column flow rate was 0.5 ml min -1 at 298 K and exposures were 2 seconds (2.1 sec. repeat time). Data acquisition and reduction analysis were carried out with Australian Synchrotron scatterBrain 9-1_0 software (Kirby et al., 2013) . Further analysis was carried out using ATSAS 2.6.0 data analysis software (Petoukhov et al., 2012) . Ab initio shape reconstructions were performed using DAMMIF (Franke and Svergun, 2009) . Shape envelope cluster analysis was performed using DAMCLUST and averaged filtered shape envelopes were generated with DAMAVER (Volkov and Svergun, 2003) . Theoretical scattering profiles were generated from model coordinates and compared to experimental data using CRYSOL (Svergun et al., 1995) . Dry volume was calculated using http://www.basic.northwestern.edu/biotools/proteincalc.html. Statistical analysis of the goodness of fit of theoretical scattering profiles to experimental SAXS data and comparisons of the fits of SAXS data were performed as in Mills et al. (Mills et al., 2009 D22A . Assays were conducted in NanoTemper standard capillaries at 90% Red LED power, 40% laser power, heated for 30 sec, followed by 5 sec cooling. All experiments were performed with a minimum of 4 independent replicates. Data points 12 µM and 24 µM for ILY wt were not included in the data analysis as these samples precipitated during assay. Affinity, K D , was quantified by analyzing the change in normalized fluorescence (Fnorm = fluorescence after thermophoresis / initial fluorescence) as a function of the concentration of the titrated protein. The percentage of ILY wt or VLY wt bound (∆Fnorm/amplitude x 100) was plotted against the concentration of protein and the experimental data points were fit with a sigmoidal function using GraphPad Prism (Version 6, GraphPad, San Diego, CA, USA) and statistical significance was assessed using an extra-sum-of-squares F test. Data are expressed as means and SEM.
Molecular Modeling
The ILY-CD59 and VLY-CD59 systems were solvated with 70,872 water molecules and 0.15 M NaCl ions added to electrostatic neutrality using VMD (Humphrey et al., 1996) . The approximate final dimensions of the systems were 121 Å x 142 Å x 214 Å. All simulations were conducted with NAMD 2.10 (Phillips et al., 2005) performed on either BlueGene/Q or Cray XC40 architecture. The systems were equilibrated using an NPT ensemble at 310 K at 1.01325 Bar for 5 nanoseconds. Long-range Coulomb forces were computed with the Particle Mesh Ewald method with a grid spacing of 1 Å. 2 fs timesteps were used with non-bonded interactions calculated every 2 fs and full electrostatics every 4 fs while hydrogens were constrained with the SHAKE algorithm. The cut-off distance was 12 Å with a switching distance of 10 Å and a pair-list distance of 14 Å. Pressure was controlled to 1 atmosphere using the Nosé-Hoover Langevin piston method employing a piston period of 100 fs and a piston decay of 50 fs. Trajectory frames were captured every 100 picoseconds. Five replicate production runs of the ILY model were run for 100 nanoseconds. The ILY-CD59 model was based on the published structure (PDB id: 4BIK) while the VLY structure was based on the one described here.
SUPPLEMENTAL ANALYSIS Related to Figures 1 to 3
VLY ml -CD59 D22A Crystallographic Dimer Despite extensive efforts we could not generate a stable complex with wild-type VLY suitable for structural studies. It is possible receptor engagement may have induced conformational changes associated with the formation of membrane-bound oligomers. However, a "monomer-locked" version of VLY, with an engineered disulfide that minimizes monomer-monomer interactions in the soluble form, did give a stable complex with CD59. The mutant design was based on a similar ILY mutant (LaChapelle et al., 2009) which prevents the disengagement of strand β5 from β4 in D3 a key step associated with the formation of membrane-bound oligomers. VLY wt residues Thr 333 and Ile 348 were mutated to cysteines to generate the disulfide bridge between β-strands 4 and 5 in D3. For the structural studies we used a modified CD59 (D22A) as this protein has been shown previously to bind with higher affinity to ILY (Wickham et al., 2011) . Two molecules of the complex were identified in the asymmetric unit of the crystal lattice and they adopt very similar structures ( Figure S1 ). The VLY ml -CD59 D22A complex forms a head-to-tail dimer in the asymmetric unit of the crystal with extensive interactions between the two VLY ml monomers, primarily through D2 but also involving residues in D4 ( Figure S1 ). Comparison of the VLY ml monomers present in the asymmetric unit shows that they are similar, with the main difference a reorientation and restructuring of D4. Superposition of each domain of molecule B on to molecule A with LSQMAN (Kleywegt and Jones, 1997) gives Cα RMSD values of D1: 1.1 Å, D2: 0.9 Å, D3: 1.3 Å and D4: 1.6 Å, with the whole protein having an RMSD of 1.9 Å or 1.5 Å for D1-3 alone. The introduced disulfide between residues 333 and 348 is clearly visible in both VLY ml molecules and results in a stretch of protein with poor definition in the experimental electron density between G339 and K346, apparently due to disruption of the β-sheet structure normally found in this part of D3. Packing between the two VLY ml chains in the asymmetric unit is extensive with a buried surface area of approximately 1,000 Å 2 split fairly evenly between the two chains (500 and 445 Å 2 for chains A and B respectively). The shape complementarity (Sc) (Lawrence and Colman, 1993; Winn et al., 2011) of the interface, 0.69, indicates tight packing, being the same order as the Sc values seen for antibody-antigen complexes of ~0.65. The interface is formed partly as a continuation of the antiparallel β-sheet that makes up D2, with the first strand of D2 from each monomer packing against each other to create what appears to be a 6-stranded continuous sheet ( Figure S1 ). The interface, however, is distorted and lacking in the classical network of backbone hydrogen bonds that are usually seen in β-sheet structures, with only a few symmetrical backbone (SerA79NH to SerB79O, SerA79O to SerB79NH) and side-chain to backbone (SerA81γO to PheB77NH, SerB81γO to PheA77NH) hydrogen bonds present. The other major interaction occurs where the loop at the end of the β-hairpin of D4 (residues T429 to G433) in each VLY ml chain inserts into the pocket formed between the equivalent loops residues and parts of D2 and D3 (residues V90, V91, E92, T302, K399, V400 and S401) on the other chain ( Figure S1 ).
Due to the arrangement of the crystallographic dimer, each CD59 D22A also makes substantial contacts with D3 of the adjacent VLY ml ( Figure S1 , S2). The CD59 D22A from one complex packs against D2 and D3 of VLY ml in the second complex. Specific interactions are limited between the proteins, with a single hydrogen bond between E76 of CD59 and T99 of VLY ml . Only slightly less surface is buried in the interface (~620 Å 2 , 320 Å 2 from VLY ml and 300 Å 2 from CD59 D22A ) than for the primary binding site, with a Sc value of 0.64. Although the Sc value is within the range of observed protein-protein interfaces (Lawrence and Colman, 1993) , the size of the interface and lack of specific interactions support the interpretation that the interaction is an artifact of the crystal lattice. This secondary site is not the same as the secondary site described in the published ILY ml -CD59 structure (Johnson et al., 2013) . The CD59 D22A component of the complex adopts an almost identical structure to the published structures of the uncomplexed protein (PDB id: 2J8B; (Leath et al., 2007) ) with a root-mean-square deviations (rmsd) of 0.4 Å and 0.3 Å over backbone alpha carbon atoms for the two CD59 D22A molecules in the asymmetric unit of the VLY ml -CD59 D22A complex crystal structure. At the site of the D22A substitution the protein structure appears unchanged, with the altered residue on the distal side of CD59 D22A with respect to the VLY ml interface (Figure 2A ). The two CD59 D22A molecules in the asymmetric unit adopt very similar structures. The largest differences are in the turn between β-strands 3 and 4, encompassing residues 31 to 33, and at the very Cterminus of the protein for chain D in the complex. The shift in position of residues 31 to 33 appears unrelated to contacts with VLY ml or to crystal contacts. The C-terminal residue, however, is in contact with VLY ml in the VLY ml -CD59 D22A complex and within the crystallographic dimer, causing it to shift relative to the free CD59 structure as discussed in the main text.
Crystal Structure of ILY ml -the Engineered Disulfide Bridge Both ILY ml monomers clearly show the presence of the disulfide ( Figure S3B ). The introduced disulfide bond causes a significant alteration of the short region from residue G352 to residue G363 as the pair of residues originally selected for site-directed mutagenesis (T346 and I361) are incorrectly oriented in the ILY wt structure for simple pairing. The two residues are in adjacent strands of the D3 beta-sheet, but on opposite faces, such that the introduction of the disulfide bond at this point causes a 180º twist and a one residue shift in register in the β-5 strand.
Crystal Structure of ILY ml Complexed to CD59 D22A -the Engineered Disulfide Bridge The electron density maps clearly supported the presence of both mutations but surprisingly there was no evidence of a disulfide bridge formed between them ( Figure S3A ), in contrast to the published low resolution structure (PDB id: 4BIK) (Johnson et al., 2013) , which also made use of the ILY ml protein and contains density consistent with an intact disulfide in both ILY ml monomers. The electron density for uncomplexed ILY ml shows the presence of the disulfide as well ( Figure S3B) . A possible explanation is that the disulfide bridge in ILY ml in the complex crystals was broken during acquisition of our data by the high energy of the synchrotron beam (Burmeister, 2000) . Nevertheless, in the CD59 D22A molecule the expected five disulfide bridges were all present. Notably the local conformation of Gly352 to Gly363 in the ILY ml protein in the complex remains in the twisted pose seen for ILY ml alone.
Crystal Structure of ILY ml Complexed to CD59 D22A -the CD59 Mutations Surprisingly, mutation of CD59 residue D22 to alanine caused a twofold increase in affinity for ILY (Wickham et al., 2011) . As with the VLY ml -CD59 D22A complex, the structure of CD59 D22A bound to ILY ml is effectively identical to the free CD59 structure (PDB id: 2J88), with a 0.8 Å alpha carbon rmsd. D22 and F23 are located in a loop distant from ILY binding site that appears structurally unchanged from the free CD59 structure ( Figure  2 ). How the D22A mutation causes increased binding is unclear, whereas the F23A mutation can be expected to destabilize the protein as the F23 aromatic ring stabilizes the position of the loop in CD59 from C19 to D24 by packing against the C19-C39 disulfide bond.
Solution Structure of ILY ml -CD59
D22A
The solution structure of the ILY ml -CD59 D22A complex was initially analyzed by SAXS in combination with size exclusion chromatography (SEC-SAXS) (Gunn et al., 2011) . The scattering species eluted in a single elution peak and Guinier analysis of these data gave a radius of gyration (R g ) of 37.4 ± 2.2 Å (Table S1 and Figure  S4B ). However, due to dilution on the column these SEC-SAXS data had a very low signal to noise and were unsuitable for shape modelling and detailed analysis. Additional SAXS data were recorded from the undiluted complex (5.6 mg/ml) in static sample mode. The R g (37.9 ± 0.2 Å) and the other invariant structural parameters obtained from the static sample were in good agreement with those from the SEC sample (Table S1 ), indicating that concentration-dependent aggregation was not an issue and all further analyses were conducted using the static SAXS data. The molecular mass of the scattering species was calculated to be 66.5 kDa using the volume estimates provided by Porod analysis of the SAXS data from the static sample and a glucose isomerase standard (172 kDa). This is in good agreement with the theoretic molecular mass of a 1:1 complex of 67.9 kDa (58.8 + 9.1 kDa, for His 6 ILY ml + CD59 D22A ). The shape of the P(r) curve generated from the static SAXS data is consistent with an elongated multi-domain structure ( Figure S4C ). Ab initio shape envelope reconstructions were performed using dummy atom modeling in DAMMIF (Franke and Svergun, 2009 ). Significant shape heterogeneity was observed in the first 10 envelopes calculated, so a total of 30 envelopes were calculated and subjected to cluster analysis using DAMCLUST. The most highly populated cluster contained 8 envelopes with mean normalized spatial discrepancy (NSD) of 0.899 ± 0.048. The average, filtered shape envelope from this most highly populated cluster overlays well with our crystallographic model of the ILY-CD59 complex ( Figure  3 ). Indeed, this cluster is more similar in shape to the crystallographic model, compared to the remaining envelopes (median NSD of 1.16, n=8; c.f. median NSD = 1.29 (n=22); p=0.033, Wilcoxon-Mann-Whitney test, 1-tailed). The theoretical scattering profile generated from the coordinates of the ILY ml -CD59 D22A crystallographic model was fitted to the static SAXS using CRYSOL (Svergun et al., 1995) ( Figure S4A ). The fit to the static SAXS data was very good (χ CRYSOL = 0.845; Pχ(χ 2 ;ν) >0.999) (statistical analysis as per Mills et al., 2009) . The fit of all alternate crystallographic 1:1 and 1:2 ILY-CD59 models, from the previously published ILY-CD59 structure (PDB id: 4BIK) (Johnson et al., 2013) , were significantly worse (χ CRYSOL >1.182; P F (F;ν 1 ,ν 2 ) <1.2e-9).
